NAOV
NanoVibronix, Inc.NASDAQHealthcare$1.90+1.06%ClosedMarket Cap: $1.5M
As of 2026-04-04
Valuation
P/E (TTM)
—
PEG
—
P/B
0.04
P/S
0.75
EV/EBITDA
0.28
DCF Value
$-109.85
FCF Yield
-335.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
30.0%
Operating Margin
-351.8%
Net Margin
-129.7%
ROE
-11.7%
ROA
-6.4%
ROIC
-20.6%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q3 2025 | $722.0K | 26.2% | $-2.2M | $510.0K | $-1.12 | — |
| Q2 2025 | $494.0K | -7.1% | $-4.0M | $-156.0K | $-1.03 | — |
| Q1 2025 | $1.0M | 36.0% | $-1.9M | $-2.5M | $-3.98 | — |
| Q4 2024 | $444.0K | 63.7% | $-1.4M | $-1.4M | $-4.21 | — |
| FY 2024 | $2.6M | 59.0% | $-3.6M | $-3.7M | $-13.73 | — |
| Q3 2024 | $376.0K | 35.4% | $-970.0K | $-998.0K | $-3.60 | — |
| Q2 2024 | $817.0K | 52.4% | $-674.0K | $-688.0K | $-2.50 | — |
| Q1 2024 | $921.0K | 72.1% | $-568.0K | $-588.0K | $-2.38 | — |
| Q4 2023 | $1.2M | 62.6% | $-702.0K | $-813.0K | $-4.00 | — |
| FY 2023 | $2.3M | 67.3% | $-3.4M | $-3.7M | $-21.20 | — |
| Q3 2023 | $458.0K | 76.2% | $-670.0K | $-727.0K | $-4.20 | — |
| Q2 2023 | $294.0K | 73.5% | $-1.0M | $-1.1M | $-6.50 | — |